• Tempus AI expanded its collaboration with Bristol Myers Squibb under a multiyear oncology data licensing agreement running through 2031.
• The agreement makes Bristol Myers Squibb one of its largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development.
• Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023516440) on October 23, 2026, and is solely responsible for the information contained therein.